Summit Therapeutics Inc. reports material agreement in SEC 8-K

Summit Therapeutics Inc. filed an 8-K covering a material definitive agreement, an unregistered sale of equity securities, charter, bylaw or fiscal-year changes, and other material corporate events. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.